العناية الفائقة والحالات الحرجة
إدارة مضاد التخثر وعكسه
Reversal of antithrombotic agents. (يفتح نافذة جديدة)
Source: Am J Hematol 2012;87 Suppl 1:S119-26.
مفهرسة: PubMed 22460529
DOI: 10.1002/ajh.23165
https://www.ncbi.nlm.nih.gov/pubmed/22460529 (يفتح نافذة جديدة)
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (يفتح نافذة جديدة)
Source: J Thromb Haemost 2015;13(10):1790-8.
مفهرسة: PubMed 26270886
DOI: 10.1111/jth.13117
https://www.ncbi.nlm.nih.gov/pubmed/26270886 (يفتح نافذة جديدة)
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (يفتح نافذة جديدة)
Source: N Engl J Med 2019;380(14):1326-35.
مفهرسة: PubMed 30730782
DOI: 10.1056/NEJMoa1814051
https://www.ncbi.nlm.nih.gov/pubmed/30730782 (يفتح نافذة جديدة)
Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (يفتح نافذة جديدة)
Source: N Engl J Med 2016;375(12):1131-41.
مفهرسة: PubMed 27573206
DOI: 10.1056/NEJMoa1607887
https://www.ncbi.nlm.nih.gov/pubmed/27573206 (يفتح نافذة جديدة)
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (يفتح نافذة جديدة)
Source: Circulation 2011;124(14):1573-9.
مفهرسة: PubMed 21900088
DOI: 10.1161/CIRCULATIONAHA.111.029017
https://www.ncbi.nlm.nih.gov/pubmed/21900088 (يفتح نافذة جديدة)
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (يفتح نافذة جديدة)
Source: Lancet 2015;385(9982):2077-87.
مفهرسة: PubMed 25728933
DOI: 10.1016/S0140-6736(14)61685-8
https://www.ncbi.nlm.nih.gov/pubmed/25728933 (يفتح نافذة جديدة)
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (يفتح نافذة جديدة)
Source: J Trauma Acute Care Surg 2013;75(3):475-86.
مفهرسة: PubMed 24089118
DOI: 10.1097/TA.0b013e3182a07391
https://www.ncbi.nlm.nih.gov/pubmed/24089118 (يفتح نافذة جديدة)
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (يفتح نافذة جديدة)
Source: Am J Hematol 2012;87 Suppl 1:S141-5.
مفهرسة: PubMed 22473649
DOI: 10.1002/ajh.23202
https://www.ncbi.nlm.nih.gov/pubmed/22473649 (يفتح نافذة جديدة)
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (يفتح نافذة جديدة)
Source: J Thromb Haemost 2011;9(9):1705-12.
مفهرسة: PubMed 21729240
DOI: 10.1111/j.1538-7836.2011.04432.x
https://www.ncbi.nlm.nih.gov/pubmed/21729240 (يفتح نافذة جديدة)
Emergency reversal of warfarin anticoagulation. (يفتح نافذة جديدة)
Source: CMAJ 2010;182(18):2004.
مفهرسة: PubMed 21078740
DOI: 10.1503/cmaj.100983
https://www.ncbi.nlm.nih.gov/pubmed/21078740 (يفتح نافذة جديدة)
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (يفتح نافذة جديدة)
Source: Thromb Haemost 2012;108(2):217-24.
مفهرسة: PubMed 22627883
DOI: 10.1160/TH12-03-0179
https://www.ncbi.nlm.nih.gov/pubmed/22627883 (يفتح نافذة جديدة)
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (يفتح نافذة جديدة)
Source: J Thromb Haemost 2008;6(4):622-31.
مفهرسة: PubMed 18208533
DOI: 10.1111/j.1538-7836.2008.02904.x
https://www.ncbi.nlm.nih.gov/pubmed/18208533 (يفتح نافذة جديدة)
Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (يفتح نافذة جديدة)
Source: Blood Adv 2019;3(2):158-67.
مفهرسة: PubMed 30658963
DOI: 10.1182/bloodadvances.2018024133
https://www.ncbi.nlm.nih.gov/pubmed/30658963 (يفتح نافذة جديدة)
Idarucizumab for dabigatran reversal. (يفتح نافذة جديدة)
Source: N Engl J Med 2015;373(6):511-20.
مفهرسة: PubMed 26095746
DOI: 10.1056/NEJMoa1502000
https://www.ncbi.nlm.nih.gov/pubmed/26095746 (يفتح نافذة جديدة)
Idarucizumab for dabigatran reversal - full cohort analysis. (يفتح نافذة جديدة)
Source: N Engl J Med 2017;377(5):431-41.
مفهرسة: PubMed 28693366
DOI: 10.1056/NEJMoa1707278
https://www.ncbi.nlm.nih.gov/pubmed/28693366 (يفتح نافذة جديدة)
Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (يفتح نافذة جديدة)
Source: Blood 2003;102(13):4594-9.
مفهرسة: PubMed 12920042
DOI: 10.1182/blood-2002-11-3566
https://www.ncbi.nlm.nih.gov/pubmed/12920042 (يفتح نافذة جديدة)
Role of agents for reversing the effects of target-specific oral anticoagulants. (يفتح نافذة جديدة)
Source: Am J Health Syst Pharm 2017;74(2):54-61.
مفهرسة: PubMed 27895055
DOI: 10.2146/ajhp150810
https://www.ncbi.nlm.nih.gov/pubmed/27895055 (يفتح نافذة جديدة)
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (يفتح نافذة جديدة)
Source: Anesth Analg 2011;113(4):703-10.
مفهرسة: PubMed 21890888
DOI: 10.1213/ANE.0b013e318228c690
https://www.ncbi.nlm.nih.gov/pubmed/21890888 (يفتح نافذة جديدة)
2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (يفتح نافذة جديدة)
Source: J Am Coll Cardiol 2017;70(24):3042-67.
مفهرسة: PubMed 29203195
DOI: 10.1016/j.jacc.2017.09.1085
https://www.ncbi.nlm.nih.gov/pubmed/29203195 (يفتح نافذة جديدة)
Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (يفتح نافذة جديدة)
Source: World Neurosurg 2014;81(1):110-5.
مفهرسة: PubMed 23220122
DOI: 10.1016/j.wneu.2012.12.002
https://www.ncbi.nlm.nih.gov/pubmed/23220122 (يفتح نافذة جديدة)
Reversal of warfarin-induced hemorrhage in the emergency department. (يفتح نافذة جديدة)
Source: West J Emerg Med 2011;12(4):386-92.
مفهرسة: PubMed 22224125
DOI: 10.5811/westjem.2011.3.2051
https://www.ncbi.nlm.nih.gov/pubmed/22224125 (يفتح نافذة جديدة)